Japan recommends its first biosimilar, Sandoz's somatropin
This article was originally published in Scrip
Japan has recommended the approval of its first therapeutic biosimilar, Sandoz's recombinant human growth hormone Somatropin BS (somatropin).
You may also be interested in...
Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.